滤泡性淋巴瘤中影响B细胞受体信号通路基因的复发性体细胞突变
对24例滤泡性淋巴瘤患者行全外显子测序,并对105例主要为初治患者的113份肿瘤样本中1716个基因进行测序,发现39个基因突变显著高于背景突变率;CREBBP突变与较差无进展生存期相关,HVCN1突变与改善的无进展生存期相关,47例(44.8%)患者存在BCR与CXCR4信号通路突变。
要点
- CREBBP突变与较差的无进展生存期相关。
- HVCN1突变与改善的无进展生存期相关。
- 47例(44.8%)患者存在BCR与CXCR4信号通路突变。
核心结论
- 本研究扩展了淋巴瘤发病机制中多个已知信号通路和复合物(BCR、Notch、SWI/SNF、液泡ATP酶)的突变基因数量,并发现EGR1/2、POU2AF1、BTK、ZNF608、HVCN1等新复发性突变需在滤泡性淋巴瘤生物学、预后和治疗背景下进一步研究。
研究设计与样本
- 对24例滤泡性淋巴瘤患者的肿瘤/正常配对样本行全外显子测序作为发现队列。
- 利用上述数据及其他B细胞恶性肿瘤中识别的突变,对来自105例主要为初治个体的113份滤泡性淋巴瘤肿瘤样本中1716个基因进行测序。
主要发现
- 识别出39个突变显著高于背景突变率的基因。
- CREBBP突变与较差的无进展生存期相关。
- 既往未报道的HVCN1(电压门控质子通道编码基因及B细胞受体信号调节因子)突变与改善的无进展生存期相关。
- 47例(44.8%)患者存在相互关联的B细胞受体(BCR)和CXCR4信号通路突变。
- 组蛋白基因突变频率高于既往报道(43.8%的患者中识别),且常共存(17.1%的患者)。
关键数值与推荐
- 在组蛋白H2B家族的一个翻译后修饰残基处识别出新的复发性热点。
局限性
- 原文指出HVCN1等新复发性突变需在滤泡性淋巴瘤生物学、预后和治疗背景下进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Follicular lymphoma (FL) is the most common form of indolent non-Hodgkin lymphoma, yet it remains only partially characterized at the genomic level. To improve our understanding of the genetic underpinnings of this incurable and clinically heterogeneous disease, whole-exome sequencing was performed on tumor/normal pairs from a discovery cohort of 24 patients with FL. Using these data and mutations identified in other B-cell malignancies, 1716 genes were sequenced in 113 FL tumor samples from 105 primarily treatment-naive individuals. We identified 39 genes that were mutated significantly above background mutation rates. CREBBP mutations were associated with inferior PFS. In contrast, mutations in previously unreported HVCN1, a voltage-gated proton channel-encoding gene and B-cell receptor signaling modulator, were associated with improved PFS. In total, 47 (44.8%) patients harbor mutations in the interconnected B-cell receptor (BCR) and CXCR4 signaling pathways. Histone gene mutations were more frequent than previously reported (identified in 43.8% of patients) and often co-occurred (17.1% of patients). A novel, recurrent hotspot was identified at a posttranslationally modified residue in the histone H2B family. This study expands the number of mutated genes described in several known signaling pathways and complexes involved in lymphoma pathogenesis (BCR, Notch, SWitch/sucrose nonfermentable (SWI/SNF), vacuolar ATPases) and identified novel recurrent mutations (EGR1/2, POU2AF1, BTK, ZNF608, HVCN1) that require further investigation in the context of FL biology, prognosis, and treatment.
引用
- Krysiak K, Gomez F, White BS, et al. Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. Blood. 2016. PMID: 28064239. doi:10.1182/blood-2016-07-729954
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。